drugset / Trial / NCT02204332
Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment
Phase 2
Terminated
38 enrolled
Hospital Clinico Universitario de Santiago
Fundación Ramón Domínguez · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine efficacy and safety of cabazitaxel administration in patients with colorectal cancer resistant to standard treatment.
Timeline
- Start
- 2013-03
- Primary completion
- 2013-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 25 mg/m2 | Intravenous |